Pancreatic Cancer Research

ResearcherKeio UniversityActive in the last 2 years

Hiroshi Nishihara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5460-8703; OpenAlex author ID A5054053950, A5123950790. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 3 papers · 2025: 2 papers

Papers 13

  1. Clinical utility of comprehensive genomic profiling for advanced pancreatic cancer: insights from real-world data analysis. Co-author DOI 10.1007/s10147-025-02713-5↗
  2. Noninvasive detection of pancreatic ductal adenocarcinoma in high-risk patients using miRNA from urinary extracellular vesicles. Co-author DOI 10.3389/fonc.2025.1682072↗
  3. A noninvasive urinary microRNA-based assay for the detection of pancreatic cancer from early to late stages: a case control study. Co-author DOI 10.1016/j.eclinm.2024.102936↗
  4. Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-72569-8↗
  5. Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid. Co-author DOI 10.3892/ol.2024.14272↗
  6. Pancreatic stellate cells derived from human pancreatic cancer demonstrate aberrant SPARC-dependent ECM remodeling in 3D engineered fibrotic tissue of clinical… Co-author DOI 10.1016/j.biomaterials.2018.11.023↗
  7. Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. Co-author DOI 10.1053/j.gastro.2018.10.029↗
  8. Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Last author DOI 10.1016/j.pan.2018.07.006↗
  9. [A Novel Treatment Strategy for Pancreatic Cancer Based on Gene Profiles]. First author PMID 27899773↗
  10. Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. Co-author DOI 10.18632/oncotarget.5729↗
  11. PDGFRβ expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker. Last author DOI 10.1007/s12032-012-0193-0↗
  12. Engineering fibrotic tissue in pancreatic cancer: a novel three-dimensional model to investigate nanoparticle delivery. Co-author DOI 10.1016/j.bbrc.2012.01.117↗
  13. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e318221bed8↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hideyuki Hayashi · 3 shared papers, 2016–2025 · strength 0.42
  2. Shutaro Hori · 2 shared papers, 2024 · strength 0.37
  3. Minoru Kitago · 2 shared papers, 2024 · strength 0.37
  4. Yuta Abe · 2 shared papers, 2024 · strength 0.37
  5. Yohei Masugi · 2 shared papers, 2024 · strength 0.37
  6. Gaku Shimane · 2 shared papers, 2024 · strength 0.37
  7. Masayuki Tanaka · 2 shared papers, 2024 · strength 0.37
  8. Yutaka Nakano · 2 shared papers, 2024 · strength 0.37
  9. Yuko Kitagawa · 2 shared papers, 2024 · strength 0.37
  10. Tomoya Kawase · 2 shared papers, 2024–2025 · strength 0.34
  11. Shogo Baba · 2 shared papers, 2024–2025 · strength 0.34
  12. Tomoyuki Satake · 2 shared papers, 2024–2025 · strength 0.34
  13. Johji Imura · 2 shared papers, 2024–2025 · strength 0.34
  14. Hiroshi Kurahara · 2 shared papers, 2024–2025 · strength 0.34
  15. Hideyuki Oi · 2 shared papers, 2024–2025 · strength 0.34
  16. Koji Yoshida · 2 shared papers, 2024–2025 · strength 0.34
  17. Takanori Kanai∥ · 1 shared paper, 2025 · strength 0.22
  18. Yasuo Hamamoto · 1 shared paper, 2025 · strength 0.22
  19. Eiichiro So · 1 shared paper, 2025 · strength 0.22
  20. Satoshi Hirano · 2 shared papers, 2015–2024 · strength 0.19
  21. Mitsunobu R. Kano · 3 shared papers, 2012–2019 · strength 0.16
  22. Yasutaka Kato · 1 shared paper, 2024 · strength 0.15
  23. Toshimichi Asano · 1 shared paper, 2024 · strength 0.15
  24. Kyoko Hida · 1 shared paper, 2024 · strength 0.15
  25. Michiya Matsusaki · 2 shared papers, 2012–2019 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.